Nimodipine

Republic of the Philippines
CEBU NORMAL UNIVERSITY

Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
DRUG STUDY
Patient’s Initials: B.T. Date of Admission: November 2, 2021 Diagnosis: Subarachnoid Hemorrhage secondary to ruptured aneurysm
Age: 49 years old Height: 5 ft. 5 inches Weight: 74 kgs. Clinical Intervention: _Surgical Clipping of Ruptured Aneurysm
Sex: Female Ward: Neuro Bed No.:6 Name of Physician: Dr. Al Garay________________________________
Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Generic Name: Pharmacologic Pharmacodynamics General Indication/s: Contraindicated in: (per system preferably) Before Drug
Nimodipine Classification: or Mechanism of Prophylaxis and Hypersensitivity; Systolic Administration:
Calcium Action: treatment of ischemic BP < 90 mm Hg; CNS: dizziness, Check the doctor’s order
Trade Name: Channel Inhibits the transport of neurological deficits Concurrent use of strong headache, abnormal Assess allergy to the drug
Nimotop Blockers calcium into vascular caused by cerebral CYP3A4 inhibitors dreams, anxiety, Obtain baseline vital signs.
smooth muscle cells, vasospasm following ( risk of hypotension); confusion, Drowsiness, Assess B/P apical pulse
Minimum Dose: resulting in inhibition of subarachnoid Concurrent use of strong nervousness, immediately before drug
5 ml/hour infused Therapeutic excitation-contraction hemorrhage of CYP3A4 inducers ( psychiatric administration (if pulse is
for the first 2 hours Classification: coupling and aneurysmal origin. efficacy). disturbances, 60/min or less or systolic
Subarachnoid subsequent contraction. Patients should be in weakness. B/P is less than 90 mmHg
Maximum Dose: hemorrhage Potent peripheral good neurological Use Cautiously in: with-hold medication,
10 ml/hour for therapy agent; vasodilator. condition post-ictus. Severe hepatic impairment EENT: blurred vision, contact physician)
succeeding hours Cerebral (dose  recommended); disturbed equilibrium, Monitor baseline hepatic
if able to tolerate Vasodilator Therapeutic Effects: Patient’s Indication: Severe renal impairment; epistaxis, tinnitus. function tests.
drug and there is Prevention of vascular Treatment of History of serious Assess neurologic status
no hypotension Pregnancy spasm after neurological deficits ventricular arrhythmias or Resp: cough, dyspnea. (LOC, movement) prior to
Category subarachnoid associated with HF; decreased GI motility; and periodically following
Patient’s Dose: C hemorrhage in subarachnoid history of bowel CV: Arrhythmias, HF, administration.
10 mg/50 ml vial, decreased neurologic hemorrhage obstruction chest pain, Caution patient of the
infuse 5 ml/hr for impairment. hypotension, different side effects
the first 2 hours; palpitations, peripheral
Prepare drugs properly at
increase to 10 edema, syncope,
the right dosage.
ml/hour for tachycardia.
Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 1 of 3
check and type the registration number)
Registration No. 52Q18778

College of Nursing
succeeding hours Pharmacokinetics:

Absorption: GI:  liver enzymes, During Drug
Route: Absorption is rapid anorexia, constipation, Administration:
Intravenous after oral and diarrhea, dry mouth, Verify patient’s identity
intravenous dysgeusia, dyspepsia, Explain to patient the
administration nausea, vomiting. purpose of medication
Frequency: Administer as a continuous
Continuous IV Distribution: GU: dysuria, nocturia, intravenous infusion via a
infusion Crosses the blood- polyuria, sexual central catheter using an
brain barrier; remainder dysfunction, urinary infusion/syringe pump. It
Availability/Form: of distribution unknown. frequency. should be given via a three-
Solution for IV way stopcock together with
infusion: 10 mg/50 Metabolism: Derm: dermatitis, PNSS solution.
mL vial Metabolized in the liver erythema multiforme, Nimodipine solution must be
flushing,  sweating, administered with a co-
Content: Excretion: photosensitivity, infusion running at a rate of
Nimodipine 0.02% ≤ 10% excreted pruritus/urticaria, rash. 40 ml/hr of either PNSS,
solution contains unchanged by kidneys; glucose 5%, lactated
the following eliminated in feces; not Endo: gynecomastia, ringers’ solution, etc.
excipients: removed by hyperglycemia. Infuse 5 mL for 2 hours. If
Ethanol 96%, hemodialysis this is well tolerated, and
Macrogol 400, Hema: anemia, particularly if there is no
sodium citrate, Onset: unknown leukopenia, marked reduction in blood
citric acid, Water thrombocytopenia. pressure, the dose is
for Injections Ph. Peak: 1 hour increased after 2 hours to
Eur. Metab: weight gain. 10 mL.
Duration: 4 hours Monitor vital signs and
MS: joint stiffness, neurologic response
Drug half-life: 1-2 hours muscle cramps. periodically during

SDF-CON-304-071-00

College of Nursing
Neuro: paresthesia, administration.

tremor.
After Drug Administration:
Misc: Stevens-Johnson Document medication
Syndrome, gingival administration correctly and
hyperplasia. accordingly.
Monitor vital signs
especially B/P (throughout
drug therapy) and
neurologic response
Monitor for adverse effects.
Monitor fluid intake and
output and assess for signs
of edema, which may
indicate fluid retention,
because drug promotes
peripheral vasodilation.
Monitor serum potassium
periodically. Hypokalemia
 risk of arrhythmias;
should be corrected.
Monitor renal and hepatic
functions periodically.
Several days of therapy may
cause hepatic enzymes,
which return to normal upon
discontinuation
of therapy.
Advise patient to avoid

SDF-CON-304-071-00

College of Nursing
grapefruit or grapefruit juice

during therapy.
Caution patient to change
positions slowly to minimize
orthostatic hypotension.
May cause drowsiness or
dizziness. Advise patient to
avoid activities requiring
alertness until response to
the medication is known.
Caution patient to wear
protective clothing and use
sunscreen to prevent
photosensitivity reactions.
References:
 Vallerand.2013. Davis’ Drug Guide for Nurses. 13th Ed. United States of America: F.A Davis Company, pp. 902-904
 Hodgson, B., & Kizior, R. (2014). Saunders nursing drug handbook 2014 (pp. 841-842). Elsevier Inc.
 Jones & Bartlett Learning. (2016). 2016 Nurse's drug handbook (pp. 848-849). Burlington, Massachusetts.
 Nimotop 0.02% Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc). (2020, July 30). Electronic Medicines Compendium.
https://www.medicines.org.uk/emc/medicine/5581/SPC#POSOLOGY

SDF-CON-304-071-00

CEBu NORMAL UNIvERSITy
College of Nursing
PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY
Student Name: Rosales, Gwyn A. Year/Section: BSN- 4B Date: Score: /30
Directions: Please select the appropriate rating using the following descriptions.
Element Very Satisfactory Satisfactory Needs Improvement Comments

Drug ☐ Accurately presented all of the patient and drug information ☐ Accurately presented most of the patient and drug ☐ Accurately presented some of the patient and drug information
Information (name [brand & generic], dosage [patient’s dose; min. & max], information related to the case. 1 missing information or error related to the case. 2 or more missing information or errors noted.
(10%) frequency, route, availability, contents) related to the case. [3] noted. [2] [1]
Classification ☐ Accurately presented the classification (therapeutic and ☐ Accurately presented the classification related to the drug ☐ Inaccurately presented the classification related to the drug.
(10%) pharmacologic) related to the drug. [3] but with 1 irrelevant information or error noted. [2] Classification is not relevant to the drug. [1]
☐ Accurately presented the indication/s (general & patient- ☐ Accurately presented the indication/s related to the drug ☐ Inaccurately presented the indication/s related to the drug.
Indication (10%) specific) related to the drug. [3] but with 1 irrelevant information or error noted. [2] Indication is not relevant to the drug. [1]
Mechanism of ☐ Accurately presented the mechanism of action ☐ Accurately presented the mechanism of action of the drug ☐ Inaccurately presented the mechanism of action of the drug.
Action (10%) (pharmacokinetics, pharmacodynamics) of the drug. [3] but with 1 irrelevant information or error noted. [2] Mechanism of action is not relevant to the drug. [1]
☐ Accurately presented all of the common contraindications ☐ Accurately presented most of the common ☐ Accurately presented some of the common contraindications
Contraindication related to the drug. [3] contraindications related to the drug. 1 missing information related to the drug. 2 or more missing information or errors noted.
(10%) or error noted. [2] [1]
Side Effects ☐ Accurately presented all of the common side effects related ☐ Accurately presented most of the common side effects ☐ Accurately presented some of the common side effects related
(10%) to the drug. [3] related to the drug. 1-2 missing information or errors noted. to the drug. 3 or more missing information or errors noted. [1]
[2]
Nursing ☐ Accurately presented all of the common nursing ☐ Accurately presented most of the common nursing ☐ Accurately presented some of the common nursing
Responsibilities responsibilities (before, during, and after) related to the drug. [9] responsibilities related to the drug. 1-2 missing information or responsibilities related to the drug. 3 or more missing information
(30%) errors noted. [7] or errors noted. [3]
☐ Presented at least 2 sources that are updated (within 5 years), ☐ Presented only one source that is updated (within 5 years), ☐ No source was presented. Sources are not updated (more than
References relevant, and credible. [3] relevant, and credible. Other sources are not updated, credible 5 years), relevant, and credible. [1]
(10%) or relevant. [2]
Sub-score = = =
Evaluated by:
Signature over Printed Name of Clinical Instructor

SDF-CON-304-071-00

Nimodipine

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Nimodipine

Uploaded by

Copyright:

Available Formats

Republic of the Philippines

CEBU NORMAL UNIVERSITY

Certification Date: 1 February 2021

Registration No. 52Q18778

succeeding hours Pharmacokinetics:

Certification Date: 1 February 2021

Registration No. 52Q18778

Neuro: paresthesia, administration.

Certification Date: 1 February 2021

Registration No. 52Q18778

grapefruit or grapefruit juice

Certification Date: 1 February 2021

Registration No. 52Q18778

PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY

Student Name: Rosales, Gwyn A. Year/Section: BSN- 4B Date: Score: /30

Element Very Satisfactory Satisfactory Needs Improvement Comments

Signature over Printed Name of Clinical Instructor

Certification Date: 1 February 2021

Registration No. 52Q18778

You might also like